Ropinirole Hcl

證據等級: L5 預測適應症: 0 個

目錄

  1. Ropinirole Hcl
  2. Ropinirole HCL: Repurposing Evaluation — Insufficient Data to Proceed
    1. One-Sentence Summary
    2. Quick Overview
    3. Why This Evaluation Cannot Proceed
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. UK Market Information
    7. Safety Considerations
    8. Conclusion and Next Steps
    9. Disclaimer
## 藥師評估報告

Ropinirole HCL: Repurposing Evaluation — Insufficient Data to Proceed

One-Sentence Summary

Ropinirole HCL has been identified as a candidate drug for repurposing analysis; however, the Evidence Pack generated for this evaluation contains critical data gaps across all key assessment domains. No predicted new indications, original indication data, mechanism of action, or UK marketing authorisation records were successfully retrieved in this pipeline run. As a result, a substantive repurposing assessment cannot be completed at this stage — this report documents the current data status and the remediation steps required before evaluation can proceed.

Quick Overview

Item Content
Drug Name (INN) Ropinirole HCL
Original Indication Not retrieved (data pipeline failure)
Predicted New Indication Not available — predicted_indications array is empty
TxGNN Prediction Score Not available
Evidence Level Cannot be determined
UK Market Status Not Marketed (0 MHRA authorisations retrieved)
Number of Marketing Authorisations 0
Recommended Decision Hold

Why This Evaluation Cannot Proceed

The Evidence Pack for this candidate was generated with inputs_received: [], indicating that the upstream data pipeline did not successfully populate the core drug record prior to Evidence Pack assembly. Two blocking or high-severity data gaps have been formally logged:

Gap ID Category Missing Item Severity Impact
DG001 Drug Level Regulatory warnings and contraindications Blocking Cannot complete S1 safety screening
DG002 Drug Level Mechanism of action (MOA) High Cannot perform mechanistic plausibility analysis

Because predicted_indications is an empty array, no TxGNN repurposing candidate has been surfaced for this drug. Without a target indication, sections covering clinical trial evidence, literature evidence, and mechanistic rationale cannot be populated.

Clinical Trial Evidence

Currently no related clinical trials registered for any predicted indication.

Literature Evidence

Currently no related literature available for any predicted indication.

UK Market Information

No MHRA marketing authorisations were retrieved for Ropinirole HCL in this Evidence Pack (total_licenses: 0, market_status: not marketed).

Note for reviewers: This result is inconsistent with expected real-world data and is likely a consequence of the pipeline data failure described above. Before concluding that no UK authorisation exists, the regulatory data retrieval step should be re-run and verified against the MHRA Product Licence register and the BNF.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

All safety fields — including key warnings, contraindications, and drug–drug interactions — returned either [Data Gap] or not_found status in this Evidence Pack. No safety data can be presented until DG001 is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete: no predicted indications were generated, no original indications were retrieved, MOA data is absent, and all safety fields are empty. Proceeding to clinical feasibility review is not possible until these gaps are remediated.

To proceed, the following is required:

  1. Re-run the data pipeline — inputs_received is empty; verify that source data files were correctly passed to the Evidence Pack generator and re-run the full pipeline for this candidate.
  2. Resolve DG001 (Blocking) — Download and parse the MHRA SmPC / TFDA product insert PDF to extract approved warnings and contraindications; this is a prerequisite for S1 safety screening.
  3. Resolve DG002 (High) — Query the DrugBank API (a successful hit with result_count: 1 was logged on 2026-03-27) to retrieve the DrugBank ID, MOA, pharmacological class, and toxicity data.
  4. Confirm UK market status — Cross-check the MHRA Product Licence register and the BNF directly to verify whether Ropinirole HCL holds any current or historical UK authorisations.
  5. Confirm DrugBank mapping — The query log records a successful DrugBank lookup (result_status: success, result_count: 1), but drugbank_id remains null in the drug record. This mapping result should be retrieved and written into the Evidence Pack.
  6. Re-run TxGNN prediction — Once original indications and DrugBank ID are confirmed, re-execute the TxGNN repurposing model to generate predicted_indications.
  7. Re-generate this report once a complete Evidence Pack (v5+) is available.

This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application. YMYL Disclaimer: the content of this report must not be used to inform prescribing decisions.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.